---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-007353"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2021-11-01T23:59:59+00:00"
generated_at: "2026-06-28T15:45:37.215315+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Corvus Q3 net loss $10.7M, cash $76.3M; mupadolimab trials enrolling

## Summary
- Net loss for Q3 2021 was $10.7M vs $9.8M in Q3 2020; R&D expenses $7.0M vs $6.6M.
- Cash, equivalents and marketable securities $76.3M at Sept 30, 2021, up $32.0M from Dec 31, 2020; FY 2021 cash burn guided ~$36M.
- Two Phase 1b/2 trials of mupadolimab + pembrolizumab enrolling: relapsed NSCLC (n=15) and HPV+ HNSCC (n=15); results expected 2022.
- Angel Pharma received IND approval in China for CPI-818 Phase 1/1b in T-cell lymphoma; trial to open early 2022.

## SEC filing metadata
- accession: 0001171843-21-007353
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2021-11-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184321007353/0001171843-21-007353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184321007353/f8k_110121.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-007353
- JSON: https://secwatch.observer/filing/0001171843-21-007353.json
- Plain text: https://secwatch.observer/filing/0001171843-21-007353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.